BTIG analyst Ryan Zimmerman upgraded GE HealthCare to Buy from Neutral with a $100 price target. After a “tough” first half of 2024 where China hurt results, the setup for GE HealthCare has improved, the analyst tells investors in a research note. The firm says the company’s guidance was reduced to effectively remove any benefit from Chinese government stimulus and now assumes declines in the Chinse market of over 20%. GE HealthCare enters the second half of 2024 with a lower bar and faces easier compares in the first half of 2024, contends BTIG.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GEHC:
- Boeing factory workers strike halts 737 MAX production: Morning Buzz
- GE HealthCare 15M share Spot Secondary priced at $86.00
- GE HealthCare announces 10M share offering of common stock for holders
- Block, GE HealthCare initiated: Wall Street’s top analyst calls
- GE HealthCare initiated with a Neutral at JPMorgan